An oral anti cancer drug. Works by inhibiting cellular signals by targeting multiple receptor tyrosine kinases (RTKs). Sunitinib is approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) Reference standards of Sunitinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => N-Nitroso N-Desethyl Sunitinib [catalogue_number] => PA 19 0751019 [category_ids] => ,70,71,78,82,117,162, [chemical_name] => [weight] => 399.43 [form] => C20H22FN5O3 [cas] => NA [pslug] => n-nitroso-n-desethyl-sunitinib-pa190751019 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 19 0751019
CAS :
Molecular Formula : C20H22FN5O3
Molecular Weight : 399.43
stdClass Object ( [pname] => (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1-nitroso-1H-pyrrole-3-carboxamide [catalogue_number] => PA 19 0751020 [category_ids] => ,82,78,71,70,162, [chemical_name] => [weight] => 427.48 [form] => C22H26FN5O3 [cas] => NA [pslug] => z-n-2-diethylamino-ethyl-5-5-fluoro-2-oxoindolin-3-ylidene-methyl-2-4-dimethyl-1-nitroso-1h-pyrrole-3-carboxamide-pa190751020 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 19 0751020
Molecular Formula : C22H26FN5O3
Molecular Weight : 427.48
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
